SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $827,348 | +118.1% | 30,009 | +137.8% | 0.02% | +110.0% |
| Q2 2023 | $379,327 | -77.5% | 12,619 | -72.9% | 0.01% | -78.3% |
| Q1 2023 | $1,685,238 | +99.7% | 46,515 | +96.6% | 0.05% | +91.7% |
| Q4 2022 | $843,952 | +127.5% | 23,660 | +96.3% | 0.02% | -22.6% |
| Q2 2021 | $371,000 | +38.4% | 12,054 | +13.2% | 0.03% | +10.7% |
| Q4 2020 | $268,000 | +4.3% | 10,650 | -1.7% | 0.03% | +86.7% |
| Q4 2019 | $257,000 | -91.2% | 10,832 | -86.9% | 0.02% | -92.7% |
| Q1 2019 | $2,905,000 | +42.5% | 82,901 | +35.1% | 0.21% | +62.2% |
| Q4 2018 | $2,039,000 | +255.2% | 61,377 | +326.5% | 0.13% | +101.6% |
| Q4 2017 | $574,000 | +3.2% | 14,392 | -34.6% | 0.06% | -28.4% |
| Q4 2016 | $556,000 | -45.9% | 22,000 | -67.4% | 0.09% | -26.7% |
| Q1 2016 | $1,028,000 | +39.5% | 67,382 | +22.9% | 0.12% | +84.6% |
| Q4 2015 | $737,000 | +3.4% | 54,815 | -7.1% | 0.06% | -11.0% |
| Q1 2015 | $713,000 | – | 59,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |